Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916934 | 0.69 | MAOA (0.42) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL10198693 | 0.69 | — | — | |
| SCHEMBL9669815 | 0.69 | HPGD (0.44) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL2588817 | 0.69 | MAPT (0.52) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL2588819 | 0.69 | MAPT (0.52) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL22606090 | 0.69 | SLC6A2 (0.30) | — | |
| SCHEMBL9671166 | 0.68 | HPGD (0.42) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL22606339 | 0.67 | POLB (0.41) | HPGDL3MBTL1KMT2AMAPTMEN1 | |
| SCHEMBL10606036 | 0.65 | — | — | |
| SCHEMBL9153017 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | MEDSHINE DISCOVERY INC. (CN) | 2021-10-05 | — | — | US | disclosed |
| EP-3738956-A1 | CXCR2 ANTAGONIST | Medshine Discovery Inc. (CN) | 2020-11-18 | — | — | EP | disclosed |
| US-20200339549-A1 | CXCR2 ANTAGONIST | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136315-B2 | CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | HPGD 416/4885L3MBTL1 4389/4885KMT2A 2784/4885 |
| US-20200339549-A1 | CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | HPGD 416/4885L3MBTL1 4389/4885KMT2A 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.